

**Kathleen A. Neville, M.D., M.S., FAAP**  
Curriculum Vitae

**GENERAL BIOGRAPHICAL INFORMATION**

PERSONAL

RESIDENCE:



BUSINESS ADDRESS: Children's Mercy Hospitals and Clinics  
2401 Gillham Road  
Kansas City, MO 64108

**EDUCATION**

UNDERGRADUATE: 1983 – 1987 University of Rochester, B.A. in English  
(Cum laude)

GRADUATE: 1991 – 1995 SUNY Health Science Center-Brooklyn - M.D.  
2002 – 2005 Indiana University – Master's Degree in Clinical  
Investigation

**ACADEMIC APPOINTMENTS**

November 2010 – Present Director, Experimental Therapeutics in Pediatric Cancer  
Children's Mercy Hospitals and Clinics  
Divisions of Pediatric Hematology/Oncology  
and Pediatric Pharmacology and Medical Toxicology  
2401 Gillham Road  
Kansas City, MO 64108

July 2010 – Present Associate Professor of Pediatrics  
Children's Mercy Hospitals and Clinics  
Divisions of Pediatric Hematology/Oncology  
and Pediatric Pharmacology and Medical Toxicology  
2401 Gillham Road  
Kansas City, MO 64108

July 2005 – June 2010 Assistant Professor of Pediatrics  
Children's Mercy Hospitals and Clinics  
Divisions of Pediatric Hematology/Oncology  
and Pediatric Pharmacology and Medical Toxicology  
2401 Gillham Road  
Kansas City, MO 64108

July 2003 – June 2005	Assistant Professor of Pediatrics and Medicine Indiana University School of Medicine James Whitcomb Riley Hospital for Children Section of Pediatric Hematology/Oncology 702 Barnhill Drive, Rm 2720 Indianapolis, IN 46202
September 2002 – June 2003	Postdoctoral Fellow, Clinical Pharmacology James Whitcomb Riley Hospital for Children Section of Pediatric Hematology/Oncology 702 Barnhill Drive, Rm 2720 Indianapolis, IN 46202
July 2001- July 2002	Instructor, Pediatric Hematology Oncology Baylor College of Medicine One Baylor Plaza Houston, TX 77030
July 1998 – June 2001	Fellow, Pediatric Hematology Oncology Baylor College of Medicine One Baylor Plaza Houston, TX 77030
July 1996 – June 1998	Resident Brown University Pediatrics Training Program Hasbro Children's Hospital 593 Eddy Street Providence, RI 02903
July 1995 – June 1996	Intern Brown University Pediatrics Training Program Hasbro Children's Hospital 593 Eddy Street Providence, RI 02903

### **OTHER ADVANCED TRAINING**

2010	Food and Drug Administration Visiting Scholar, Office of Clinical Pharmacology
2008	SPSS v16 Training Course
2007	WinNonlin v 5.2 Training Course
2007	NIH Clinical Pharmacology Course
2002	Pharmacology of Anticancer Agents: Cancer Education Consortium
2001	Pediatric Pharmacology; American Society for Clinical Pharmacology and Therapeutics
2001	Methods in Clinical Cancer Research; American Association for Cancer Research
2000	Clinical Epidemiology and Trial Design; Berlex Oncology Foundation.

2000 Molecular Biology in Clinical Oncology; American Association for Cancer Research

### **BOARD CERTIFICATIONS**

1999, 2007 American Board of Pediatrics: Pediatrics  
 2002, 2012 American Board of Pediatrics: Pediatric Hematology/Oncology  
 2007 American Board of Clinical Pharmacology: Clinical Pharmacology

### **HONORS AND AWARDS**

1999 Nirken Fellow, Baylor College of Medicine  
 1998 Haffenreffer Award for Outstanding Residency Service, Rhode Island Hospital  
 1994 Nominated, Alpha Omega Alpha

### **NATIONAL SCIENTIFIC PARTICIPATION**

#### PROFESSIONAL SOCIETIES

2002– PRESENT Member of American Society for Pediatric Hematology/Oncology  
 2002– PRESENT Member of American Society for Clinical Pharmacology and Therapeutics  
 2002– PRESENT Member of American Society of Hematology  
 2001– PRESENT Member of the Children’s Oncology Group  
 2000– 2002 Member of American Association of Cancer Research  
 1995– PRESENT Member of American Academy of Pediatrics  
 1991– 1998 Member of American Medical Association

#### COMMITTEES

2013 – PRESENT Chair, American Academy of Pediatrics Committee on Drugs  
 2012 Review Panel, Comprehensive Sickle Cell Centers (U54), NHLBI  
 2012 – PRESENT Food and Drug Administration, Advisory Committee for Pharmaceutical Science and Clinical Pharmacology  
 2012 – PRESENT Steering Committee, Stroke Prevention in Nigeria (SPIN) Trial  
 2012 – PRESENT Presidential Advisor, American Society for Clinical Pharmacology and Therapeutics Education Committee  
 2012 – PRESENT Chair, American Society for Clinical Pharmacology and Therapeutics Mentoring Task Force  
 2011 – PRESENT American Academy of Pediatrics Committee on Drugs  
 2011 – 2013 Data Safety Monitoring Board, Neuroblastoma Medulloblastoma Treatment Research Consortium  
 2010 – PRESENT Review Panel, National Institute of General Medical Sciences, Loan Repayment Program  
 2010 – 2013 Food and Drug Administration, Pediatric Advisory Committee, Consultant  
 2010 – PRESENT Food and Drug Administration, Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee  
 2010 – 2013 Data Safety Monitoring Board, NHLBI, Intravenous Magnesium for Sickle Cell Vaso-occlusive Crisis (MAGIC) Study

2009 – 2012	Chair, Education Committee, American Society for Clinical Pharmacology and Therapeutics
2009 – 2012	University of Missouri—Kansas City School of Medicine, Council on Curriculum
2007 – 2009	Vice Chair, Continuing Medical Education, American Society for Clinical Pharmacology and Therapeutics Education Committee
2006 – 2012	American Society for Clinical Pharmacology and Therapeutics Education Committee
2008	Co-Chair, Grant Writing Institute for Sickle Cell Disease, Memorial Healthcare System
2007-2008	Children's Mercy Hospital, Pharmacy and Therapeutics Committee
2007	Review Panel, Comprehensive Sickle Cell Centers (U54), NHLBI
2007	Working Group in Sickle Cell Disease: Neurobiology of Pain and Pharmacogenetics, NHLBI
2003 – 2006	American Society for Clinical Pharmacology and Therapeutics Scientific Program Committee
2001 – 2002	Baylor College of Medicine Human Subjects Institutional Review Board
1999 – 2001	Texas Children's Cancer Center Fellowship Education Committee
1999 – 2001	Texas Children's Cancer Center Fellowship Orientation Committee

#### EDITORIAL BOARD

2011- PRESENT      Pediatric Drugs

#### ADHOC REVIEWER

Clinical Pharmacology & Therapeutics  
 British Journal of Clinical Pharmacology  
 Bone Marrow Transplantation  
 Journal of Pediatric Hematology/Oncology  
 Cancer Chemotherapeutics and Pharmacology  
 American Journal of Hematology  
 Pediatric Blood and Cancer

#### **PUBLICATIONS**

##### FULL PAPERS

1. **Neville K**, Bromberg A, Bromberg R, Bonk S, Hanna BA, Rom WN. The third epidemic - multidrug resistant tuberculosis. *Chest* 1994; 105:45-48.
2. **Neville KA**, Renbarger JL, and Dreyer ZE. Pneumonia in the immunocompromised cancer patient. *Semin Respir Infect*, 2002; 17:21-32.
3. **Neville K**, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM, McGuffey L, McCully C, Berg SL, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. *Clin Cancer Res* 2004; 10(7):2525-9
4. **Neville K**, Blaney S, Bernstein M, Thompson P, Adams D, Aleksic A, Berg S. Pharmacokinetics of O6-benzylguanine in Pediatric Patients with Central Nervous System Tumors: A Pediatric Oncology Group study. *Clin Cancer Res* 2004; 10(15):5072-5.

5. Blaney SM, Bernstein M, **Neville K**, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC. A phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: A Children's Oncology Group study (ADV0015). *J Clin Oncol* 2004; 22:4752-4757.
6. **Neville KA**, Blaney SM. Leptomeningeal cancer in the pediatric patient. *Cancer Treat Res* 2005; 125:87-106.
7. Bernard S, **Neville KA**, Nguyen AT, and Flockhart D. Interethnic differences in CYP2D6 polymorphisms with a focus on 5-HT<sub>3</sub> receptor antagonists. *Oncologist* 2006; 11:126-35.
8. Atluri S, **Neville K**, Davis M, Robertson KA, Marshalleck FE, O'Malley DP, Buckley RH, Nelson RP Jr. Epstein-Barr-associated leiomyomatosis and T-cell chimerism after haploidentical bone marrow transplantation for severe combined immunodeficiency disease. *J Pediatr Hematol Oncol* 2007; 29:166-172.
9. Adams DM, Zhou T, Berg SL, Bernstein M, **Neville K**, Blaney SM. Phase 1 trial of O(6)-benzylguanine and BCNU in children with CNS tumors: A Children's Oncology Group study. *Pediatr Blood Cancer* 2008; 50:549-53.
10. **Neville KA**, Wicklund BM, Kearns GL. Genetics of warfarin response. *N Engl J Med* 2008; 358:2742.
11. Iyengar SS, Olitsky SE, and **Neville KA**. Diagnosis of Factor XI Deficiency Following Congenital Cataract Extraction. *J AAPOS* 2008; 12:297-8.
12. **Neville K**, Szeffler SJ, Abdel-Rahman SM, Lahu G, Zech K, Herzog R, Bethke TD, Gleason M and Kearns GL. Single-dose pharmacokinetics of roflumilast in children and adolescents. *J Clin Pharmacol* 2008; 48:978-85.
13. von Baeyer CL, Spagrud LJ, McCormick JC, Choo E, **Neville K**, and Connelly, M.A. Three new datasets supporting use of the Numerical Rating Scale (NRS-11) for children's self-reports of pain intensity. *Pain* 2009; 143:223-7.
14. Jones BL, Abdel-Rahman SM, Simon SD, Kearns GL, and **Neville KA**. Assessment of histamine pharmacodynamics by microvasculature response of histamine using histamine iontophoresis laser Doppler flowimetry. *J Clin Pharmacol* 2009; 49:600-605.
15. Dalal J, **Neville KA**. Busulfan in children: Impact of development on dose-exposure-response relationship? *Pediatr Blood Cancer* 2010; 54:191-2.
16. Scott DK, **Neville K**, Garg U. Determination of hydroxyurea in serum or plasma using gas chromatography-mass spectrometry (GC-MS). *Methods Mol Biol* 2010; 603:279-87.
17. Connelly M and **Neville K**. Comparative prospective evaluation of the responsiveness of single-item pediatric pain intensity self-report scales and their uniqueness from negative affect in a hospital setting. *J Pain* 2010; 11:1451-60.

18. **Neville KA**. Continuing education reform: are we throwing the baby out with the bathwater? *Clin Pharmacol Ther* 2010; 87:385-8.
19. Heruth DP, Hawkins T, Logsdon DP, Gibson MI, Sokolovsky IV, Nsumu NN, Major SL, Fegley B, Woods GM, Lewing KB, **Neville KA**, Cornetta K, Peterson KR, White RA. Mutation in erythroid specific transcription factor KLF1 causes Hereditary Spherocytosis in the Nan hemolytic anemia mouse model. *Genomics* 2010; 96:303-307.
20. **Neville KA** and Panepinto JA. Pharmacotherapy of Sickle Cell Disease. 18th Expert Committee on the Selection and Use of Essential Medicines. World Health Organization. [http://www.who.int/selection\\_medicines/committees/expert/18/applications/Sicklecell.pdf](http://www.who.int/selection_medicines/committees/expert/18/applications/Sicklecell.pdf)
21. **Neville KA**, Becker ML, Goldman JL, and Kearns GL. Developmental pharmacogenomics. *Paediatr Anaesth* 2011; 21:255-65.
22. Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, Smith WR, Galacteros F, Kutlar A, Hull JH, Stocker JW; **ICA-17043-10 Study Investigators**. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). *Br J Haematol* 2011; 153:92-104.
23. Guest EM, **Neville KA**, Hoyer JD, Safo MK, Garg U, Saunders CJ, Abdulmalik O, Zwick DL. Hb Lake Tapawingo [ $\alpha$ 46(CE4)Phe $\rightarrow$ Ser; HBA2:c.140T>C]: a new unstable  $\alpha$  chain hemoglobin variant associated with low systemic arterial saturation. *Hemoglobin* 2011; 35:411-6.
24. Myers AL, Gaedigk A, Dai H, James LP, Jones BL, **Neville KA**. Defining Risk Factors for Red Man Syndrome in Children and Adults. *Pediatr Infect Dis J* 2012; Feb 9.
25. Hudak ML, Tan RC; **Committee on Drugs**; Committee on Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal. *Pediatrics* 2012; 129:e540-60.
26. Flatt T, **Neville K**, Lewing K, Dalal J. Successful treatment of fanconi anemia and T-cell acute lymphoblastic leukemia. *Case Rep Hematol* 2012; 2012:396395.
27. Shakhnovich V, Daniel J, Wicklund B, Kearns G, **Neville K**. Use of pharmacokinetic modelling to individualize FFP dosing in factor V deficiency. *Haemophilia* 2013; 19:251-5.
28. Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, **Neville KA**, Hoppe C, Barral S. Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea. *PLoS One* 2013; 8:e55709
29. August K J, Narendran A, **Neville KA**. Pediatric Relapsed or Refractory Leukemia: New Pharmacotherapeutic Developments and Future Directions. *Drugs* 2013;73(5):439-61.

30. Jones BL, Kearns G, **Neville KA**, Sherwin CM, Spigarelli MM, Leeder JS. Variability of histamine pharmacodynamic response in children with allergic rhinitis. *J Clin Pharmacol* 2013; 53(7):731-7.

31. Sachs HC and **Committee on Drugs**. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. *Pediatrics* 2013; 132(3):e796-809.

32. August KJ, Narendran A, **Neville KA** . Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions. *Drugs* 2013; 73(5):439-61

33. Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, **Neville KA**, Hoppe C, Barral S. Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea. *PLoS One*. 2013; 8(2):e55709.

34. Flatt T, **Neville K**, Lewing K, Dalal J. Successful treatment of fanconi anemia and T-cell acute lymphoblastic leukemia. *Case Rep Hematol* 2012; 2012:396395.

35. Galinkin J, Koh JL; **Committee on Drugs**. Recognition and management of iatrogenically induced opioid dependence and withdrawal in children. *Pediatrics* 2011; 133(1):152-5.

36. Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, **Neville K**, Leeder JS, Hayden MR, Ross CJ, Carleton BC. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. *Pediatr Blood Cancer* 2014; 61(6):1055-62.

37. Frattarelli DA, Galinkin JL, Green TP, Johnson TD, **Neville KA (lead author)**, Paul IM, Van Den Anker JN and **Committee on Drugs**. Off-label use of drugs in children. *Pediatrics* 2014; 133(3):563-7.

38. Wiczling P, Liem RI, Panepinto JA, Garg U, Abdel-Rahman SM, Kearns GL, **Neville KA**. Population Pharmacokinetics of Hydroxyurea for Children and Adolescents with Sickle Cell Disease. *J Clin Pharmacol* 2014; Apr 3

39. [Redacted] (b) (4)

40. [Redacted] (b) (4)

41. [Redacted] (b) (4)

42. [Redacted] (b) (4)

43. [REDACTED] (b) (4)

## ABSTRACTS

1. **Neville K**, Blaney S, Bernstein M, Thompson P, Adams D, Aleksic A, Berg S. Pharmacokinetics of O<sup>6</sup>-benzylguanine in children: A Pediatric Oncology Group study. *Proceedings of the AACR 2001*; 42:411.
2. **Neville KA**, Ajayi OE, Ho H, Holland CL, Skaar TC, and Hall SD. Association between CYP3A5 and blood pressure in Nigerian Males. *Clin Pharmacol Ther* 2005; 77:55.
3. **Neville KA**, Skaar TC, Heiny ME, Kearns GL, Flockhart DA. Frequency of eNOS polymorphisms in pediatric patients with sickle cell disease. *Clin Pharmacol Ther* 2005; 77:16.
4. **Neville KA**, Stegenga, KA, Rachel JM, Woods GM, Simon SD and Zucker ML. Prothrombin gene mutation 20209 is not associated with stroke in pediatric patients with sickle cell disease. *Clin Pharmacol Ther* 2007; 81:S93.
5. **Neville KA**, Jones BL, Abdel-Rahman SM, Kearns GL. Iontophoresis with laser Doppler flowimetry as a pharmacodynamic tool for histamine response. *Clin Pharmacol Ther* 2007; 81:S93.
6. **Neville KA**, Connelly M, Anderson, Griggs R, St. Peter S. Clinical applications of quantitative pupillometry: What can children's eyes tell us about pain and treatment response? *International Symposium on Pediatric Pain*, March, 2010.
7. Connelly M, Anderson R, Griggs R, St. Peter S, **Neville K**. Measures of pediatric pain intensity in the inpatient hospital setting: Are they comparable? *International Symposium on Pediatric Pain*, March, 2010.
8. Guest EM, **Neville KA**, Hoyer JD, Safo MK, Garg U, Saunders CJ, Abdulmalik O, Zwick DL. Hemoglobin Kansas City: a new unstable alpha chain variant hemoglobin associated with low systemic arterial saturation. *Pediatr Blood Cancer* 2009; 52:726.
9. Flatt T, Lewing K, **Neville K**, and Dalal J. Successful treatment with bone marrow transplant for a patient with fanconi anemia, T-cell acute lymphoblastic leukemia, and disseminated aspergillosis. *Pediatr Blood Cancer* 2009; 52:707.
10. Myers AL, Gaedigk A, Jones BL, James LP, **Neville KA**. Incidence and characteristics of red man syndrome in children and association with gene polymorphisms for histamine degradation. *47th Annual Meeting of the Infectious Diseases Society of America*, October, 2009.

11. **Neville KA**, Anderson R, Griggs M, St. Peter S, Connelly M. Pupillometry: a tool to measure pharmacodynamic effect of analgesic drugs in pediatrics. *Clin Pharmacol Ther* 2010; 87: S65-S67.
12. **Neville KA**, Kearns GL, Daniel JF, Andrews WS, Wicklund BM. Pharmacokinetic (PK) modeling of factor V activity accurately predicts Factor V levels after treatment with fresh frozen plasma. Accepted, *16th World Congress of Basic and Clinical Pharmacology, World Pharma 2010*, July 2010.
13. **Neville KA**, Liem RI, Panepinto JA Panepinto, Garg U, Pearce R, Kearns GK, and Abdel-Rahman S. Single-dose (SD and steady-state (SS) pharmacokinetics of hydroxyurea in children and adolescents with sickle cell disease. *American Society of Pediatric Hematology Oncology*, 2011.
14. Brown J, Nickols C, Connelly M, Weigel J, **Neville K**. Developmental Changes of Normal Pupil Size and Reactivity in Children 1-17 Years. *Clin Pharmacol Ther* 2013; 93: S14.

#### BOOK CHAPTERS

1. Lee TH and **Neville KA**. Barometric medicine. In: Rom WN (ed). *Environmental and Occupational Medicine*, 2<sup>nd</sup> ed. Little, Brown and Company, Boston, 1992, pp. 1133-1142.
2. **Neville KA**, Blake MJ, and Kearns GL. Pediatric Clinical Pharmacology. In: Waldman SA and Terzec A (eds). *Pharmacology and Therapeutics: Principles and Practice*. Saunders Elsevier, New York, 2009, pp. 239-249.
3. Kearns GL, Wilson JT, **Neville KA**, and Springer MA. Drug Therapy in Pediatric Patients. In: van Boxtel CJ, Santoso B, Edwards IR (eds). *Drug Benefits and Risks: International Textbook of Clinical Pharmacology*, 2<sup>nd</sup> ed. John Wiley & Sons, Inc., New York, NY, 2008, pp. 181-201.
4. **Neville KA**. Pediatric Pharmacokinetics. In: Ritschel WA and Kearns GL (eds). *Handbook of Basic Pharmacokinetics Including Clinical Applications*, 7<sup>th</sup> ed. American Pharmacists Association, Washington, DC, 2009, pp. 263-278.
5. Scott DK, **Neville K** and Garg U. Determination of Hydroxyurea in Serum or Plasma using Gas Chromatography-Mass Spectrometry (GC/MS). In: Garg U and Hammett-Stabler C (eds). *Clinical Applications of Mass Spectrometry*. Humana Press, New York, NY, 2010, pp. 279-87.
6. **Neville KA**, Wicklund BM, and Woods GM. Coagulopathies and Sickle Cell Disease. In: Ashcraft KW, Holcomb GW, and Murphy JP (eds). *Pediatric Surgery*. Elsevier, New York, 2010, pp. 61-73.
7. **Neville KA** and Leeder JS. Pediatric Pharmacogenetics and Pharmacogenomics, and Pharmacoproteomics. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BMD (eds). *Nelson's Textbook of Pediatrics*, 19<sup>th</sup> ed., Saunders, New York, 2010 (last updated 2014).

## OTHER

1. **Neville KA**, Steuber CP. Clinical assessment of the child with suspected cancer-I & II.. In: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA 2003 (last update Oct 2012).

**TEACHING INFORMATION**

## LECTURES

- 2013 Nationwide Children's Hospital, invited lecture. *Clinical Trials in Children*
- 2013 NICHD T32 Yaffe Lecture Series invited lecture. *Pediatric Clinical Trials*
- 2013 American Society for Clinical Pharmacology and Therapeutics Annual Meeting invited lecture. *Holding an IND*
- 2013 American Society for Clinical Pharmacology and Therapeutics Annual Meeting invited lecture. *Pediatric Clinical Pharmacology Review*
- 2012 American Society for Clinical Pharmacology and Therapeutics Annual Meeting invited workshop. *How to Find a Mentor*
- 2011 American Society for Clinical Pharmacology and Therapeutics Annual Meeting invited symposium. *It's all Physiology: Why Children are not "little" Adults*
- 2011 American Society for Clinical Pharmacology and Therapeutics Annual Meeting invited workshop. *Pediatric Pain: Bridging the Gap between Evaluation and Treatment*
- 2009 Louisiana State University School of Medicine-Shreveport, Grand Rounds. *Experimental Therapeutics: From Test Tube to Treatment*
- 2008 University of Arkansas Medical School, Fellow's Day. *How to Find a Mentor.*
- 2008 University of Arkansas Medical School, Grand Rounds. *Challenges in Pediatric Pain*
- 2008 Brown University, Hasbro Children's Hospital, Grand Rounds. *Challenges in Pediatric Pain.*
- 2008 Grant Writing Institute for Sickle Cell Disease, Memorial Healthcare System. *Overview for writing a K23.*
- 2007 Sickle Cell Educational and Research Workshop, Memorial Healthcare System. *Overview for writing a K23*
- 2007 Resident Core Lectures, Children's Mercy Hospital. *Board Review: Hematology.*
- 2006 Medical Staff Series, Children's Mercy Hospital. *Clinical and Research aspects of Pediatric Sickle Cell Disease.*
- 2005 Resident Core Lectures, Children's Mercy Hospital. *Anemia in the Pediatric Patient*
- 2004 Resident Core lectures, Indiana University. *Sickle Cell Disease, Oncologic Emergencies*
- 2003 Resident Noon Conference, Indiana University. *Pediatric Clinical Pharmacology*
- 1999 Resident Clinical Pathologic Conference, Baylor College of Medicine. *Megaloblastic Anemia.*

## OTHER PRESENTATIONS

- 2014 Food and Drug Administration. *The Monograph Process* (testimony on behalf of AAP)
- 2014 Sirius XM (Dr. Radio). Invited guest: Off-label use of drugs in children
- 2014 Sirius XM (Dr. Radio). Invited guest: Early phase trials in pediatric oncology
- 2014 AAP radio. Use of codeine in the emergency room
- 2008 Invited Host, University of Arkansas School of Medicine, Arkansas Children's Hospital, Fellow's Day.

2007 Working Group in Sickle Cell Disease: Neurobiology of Pain and Pharmacogenetics, NHLBI. *Developmental Pharmacology in Children: Implications for Sickle Cell Disease Pain and Analgesia.*

2007 Working Group in Sickle Cell Disease: Neurobiology of Pain and Pharmacogenetics, NHLBI. *Pharmacogenomics in Sickle Cell Disease: African Data.*

## INTERNATIONAL

1999 Teleconference with King Faisal Hospital Division of Hematology/Oncology, Saudi Arabia. *Adrenocortical Carcinoma.*

## OTHER INFORMATION

### RESEARCH FUNDING

#### Ongoing Research Support

NICHD/Pediatric Trials Network Neville (Sub-PI, IND holder) 9/11-6/30/14  
*Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients with Sickle Cell Anemia.*

The goal of this project is to gather pharmacokinetic data sufficient for pediatric labeling for a hydroxyurea liquid formulation and to compare relative bioavailability between liquid and capsule formulations.

Midwest Cancer Alliance Neville (PI) 8/1/10-7/30/14

*Standardization of a liquid formulation of 6-mercaptopurine for pediatric cancer treatment*

The goal of this project is to develop a consistent, standardized formulation of 6-mercaptopurine for use in children.

#### Completed Research Support

K23 HL077684-01A2 Neville (PI) 5/01/06-10/30/11  
NHBLI

*Pharmacogenetics of Pediatric Sickle Cell Disease*

The goal of this study is to address both the mechanisms involved in the pathogenesis of vaso-occlusive crisis as well as the pharmacologic barriers to successful treatment with hydroxyurea, a drug that targets disease pathogenesis.

Marion Merrell Dow Clinical Scholars Award Neville (PI) 1/01/06-12/31/11

*Pharmacogenetics of Pediatric Sickle Cell Disease*

This project addresses how genetic factors which influence both the severity sickle cell disease and, potentially, the metabolism of hydroxyurea interact to alter the response to drug treatment.

## NATIONAL PROTOCOLS CHAIRED

Pediatric Trials Network 12/10-present

*Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients with Sickle Cell Anemia.*

Kathleen Neville, M.D.

6/17/14

Food and Drug Administration

11/08-present

*Warfarin Pharmacogenetics in Pediatric Patients.*

Abbott Laboratories.

10/09-4/09

*An Open-label Pharmacokinetic Study of Hydrocodone/Acetaminophen in Children Ages 6 to 17 with Moderate to Moderately Severe Postoperative Pain.*

Children's Oncology Group #ADV L0015.

4/01-7/02

*A Phase I Study of PS-341 in Pediatric Patients with Refractory Solid Tumors.*